Skip directly to content

Cresemba® (isavuconazole)

What is Cresemba and what is it used for?

Cresemba is an antifungal medicine that works by blocking the production of a key component of the cell membrane of fungi. This weakens the membrane, therefore preventing fungal cell growth.

Cresemba is available as capsules and in an injectable form. In adults (aged 18 and over), it can be used to treat:

  • invasive aspergillosis
  • mucormycosis in patients for whom amphotericin B is inappropriate.

These fungal infections may occur in patients being treated for blood cancers, transplant recipients and patients in intensive care units. They are challenging to treat and have a high mortality rate.

The medicine can only be obtained with a prescription.


Reference information

The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See EMA guidance on Cresemba.

If you would like to see the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SPC) for Cresemba these can be found at the electronic Medicines Compendium (eMC).


Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

PP-CRB-GBR-0925 / Jan 2021